NEW INFORMATION: FDA panel backs Gilead Sciences' hepatitis C drug

By: AP Email
By: AP Email

WASHINGTON (AP) -- Food and Drug Administration advisers have unanimously voted in favor of a highly anticipated hepatitis C drug from Gilead Sciences that holds promise for millions of Americans infected with the liver-destroying virus.

All 15 members of the FDA's panel of virus experts voted to recommend approval of Gilead's pill to treat several forms of hepatitis C that account for most cases in the U.S.

About 3 million people in the U.S. have hepatitis C, a blood-borne disease that causes liver damage. It is blamed for 15,000 deaths annually.

Current treatments can take up to a year of therapy and only cure about three out of four patients. Gilead's daily pill can cure up to 90 percent of patients with the most common form of the virus in just 12 weeks.


Comments are posted from viewers like you and do not always reflect the views of this station.
powered by Disqus
WEAU 13 NEWS 1907 S. Hastings Way Eau Claire, WI 54701 By Phone: Main Number (715) 835-1313 and (715) 832-3474. Tip Line (715) 839-WEAU - (715) 839-9328 Sports Line (715) 852-1537
Gray Television, Inc. - Copyright © 2002-2014 - Designed by Gray Digital Media - Powered by Clickability 229293011 - weau.com/a?a=229293011